Yarrow Bioscience Inc
YARWHealthcare|Biotechnology|US
$15.60
+2.00 (+14.71%)
DCF Value
$23.72
Tangible Book / Share
$25.71
Cash / Share
$26.72
Financials
Financial Snapshot
Market Cap
$145.1M
Enterprise Value
$122.2M
Revenue (TTM)
$482.0K
Net Income (TTM)
-$18.7M
Cash & Investments
$22.9M
Net Cash
$22.9M
Free Cash Flow (TTM)
-$16.9M
Operating CF (TTM)
-$16.9M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$22.9M
Quarterly Burn
$4.2M
Monthly Burn
$1.4M
Est. Runway
~5.4 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $30.9M | $62.5M | $136.3M | $76.9M | $58.6M | $42.3M | $30.9M | $93.3M | $61.5M | $29.0M | $22.9M | |
| Operating Cash Flow | -$2.3M | -$28.2M | -$52.7M | -$65.1M | -$137.1M | -$56.4M | -$29.2M | -$25.3M | -$34.0M | -$33.1M | -$16.9M | |
| Free Cash Flow | -$2.3M | -$28.3M | -$52.9M | -$65.1M | -$137.2M | -$56.4M | -$29.2M | -$25.3M | -$34.1M | -$33.1M | -$16.9M | |
| Capital Expenditure | -$31.0K | -$27.0K | -$140.0K | -$11.0K | -$113.0K | $0.00 | $0.00 | $0.00 | -$117.0K | $0.00 | $0.00 | |
| Financing Cash Flow | $0.00 | $49.5M | $125.9M | $5.0M | $61.8M | $39.8M | $1.7M | $82.4M | -$141.0K | -$143.0K | -$51.0K |
R&D Spending
R&D (TTM)
$9.8M
R&D Intensity
2041.1%
R&D Growth vs Prior
-48.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $674.0K | $4.6M | $10.6M | $443.0K | $21.0M | $931.0K | $477.0K | $424.0K | $501.0K | $570.0K | $482.0K | |
| R&D Expense | $11.3M | $29.0M | $53.0M | $53.8M | $43.5M | $19.5M | $18.4M | $16.3M | $30.9M | $19.2M | $9.8M | |
| R&D % of Revenue | 1669.9% | 633.1% | 498.0% | 12135.7% | 207.4% | 2099.1% | 3854.3% | 3846.0% | 6176.8% | 3374.9% | 2041.1% | |
| SG&A | $3.8M | $5.2M | $12.2M | $22.5M | $89.5M | $20.3M | $16.4M | $13.4M | $13.2M | $11.1M | $10.6M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $674.0K | $4.6M | $10.6M | $443.0K | $21.0M | $931.0K | $477.0K | $424.0K | $501.0K | $570.0K | $482.0K | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $350.0K | $1.4M | $0.00 | $0.00 | $0.00 | $0.00 | $23.0K | $12.0K | |
| Gross Profit | $674.0K | $4.6M | $10.6M | $93.0K | $19.6M | $931.0K | $477.0K | $424.0K | $501.0K | $547.0K | $470.0K | |
| R&D | $11.3M | $29.0M | $53.0M | $53.8M | $43.5M | $19.5M | $18.4M | $16.3M | $30.9M | $19.2M | $9.8M | |
| SG&A | $3.8M | $5.2M | $12.2M | $22.5M | $89.5M | $20.3M | $16.4M | $13.4M | $13.2M | $11.1M | $10.6M | |
| Operating Income | -$14.3M | -$29.6M | -$54.5M | -$76.2M | $252.5M | -$38.9M | -$34.3M | -$29.3M | -$43.6M | -$29.7M | -$19.9M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $921.0K | $4.4M | $5.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$14.1M | -$29.1M | -$51.4M | -$73.7M | -$255.8M | -$43.8M | -$33.9M | -$27.9M | -$39.8M | -$26.7M | -$18.9M | |
| Net Income | -$14.1M | -$29.1M | -$51.4M | -$70.5M | -$255.6M | -$73.3M | -$23.2M | -$28.5M | -$39.8M | -$26.5M | -$18.7M | |
| EPS (Diluted) | -2204.06 | -4555.37 | -8546.98 | -10095.00 | -7095.17 | -1282.44 | -566.98 | -138.48 | -46.77 | -30.96 | -23.45 | |
| EBITDA | -$14.3M | -$29.6M | -$54.5M | -$94.1M | -$251.1M | -$38.0M | -$33.9M | -$27.9M | -$39.8M | -$26.7M | -$18.8M | |
| Shares Out. (M) | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.06 | 0.06 | 0.21 | 0.85 | 0.86 | 0.86 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.0M | $10.2M | $49.5M | $30.8M | $57.6M | $42.3M | $30.9M | $30.6M | $19.9M | $24.0M | $22.9M | |
| Short-Term Investments | $26.9M | $49.3M | $86.7M | $46.2M | $1.0M | $0.00 | $0.00 | $62.6M | $41.6M | $5.0M | $0.00 | |
| Total Current Assets | $31.5M | $63.9M | $139.5M | $78.3M | $87.3M | $63.2M | $38.3M | $96.0M | $64.4M | $30.0M | $23.5M | |
| Total Assets | $42.1M | $66.9M | $139.9M | $79.2M | $93.7M | $67.0M | $40.8M | $97.7M | $66.9M | $30.2M | $23.6M | |
| Total Current Liabilities | $3.9M | $7.8M | $9.5M | $10.7M | $21.8M | $18.4M | $9.3M | $7.5M | $14.8M | $2.4M | $1.5M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $33.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $71.5M | $123.9M | $9.6M | $10.7M | $56.2M | $18.4M | $9.6M | $8.9M | $14.8M | $2.4M | $1.5M | |
| Stockholders' Equity | -$29.4M | -$57.0M | $130.4M | $68.5M | $37.5M | $48.6M | $31.2M | $88.7M | $52.1M | $27.8M | $22.1M | |
| Retained Earnings | -$30.1M | -$59.2M | -$110.6M | -$184.3M | -$566.2M | -$639.5M | -$662.7M | -$691.3M | -$731.2M | -$757.7M | -$764.2M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.3M | -$28.2M | -$52.7M | -$65.1M | -$137.1M | -$56.4M | -$29.2M | -$25.3M | -$34.0M | -$33.1M | -$16.9M | |
| Capital Expenditure | -$31.0K | -$27.0K | -$140.0K | -$11.0K | -$113.0K | $0.00 | $0.00 | $0.00 | -$117.0K | $0.00 | $0.00 | |
| Free Cash Flow | -$2.3M | -$28.3M | -$52.9M | -$65.1M | -$137.2M | -$56.4M | -$29.2M | -$25.3M | -$34.1M | -$33.1M | -$16.9M | |
| Investing Cash Flow | -$37.5M | -$15.1M | -$33.9M | $41.4M | $89.1M | $1.0M | $15.7M | -$57.4M | $23.4M | $37.4M | $17.9M | |
| Financing Cash Flow | $0.00 | $49.5M | $125.9M | $5.0M | $61.8M | $39.8M | $1.7M | $82.4M | -$141.0K | -$143.0K | -$51.0K | |
| Issuance of Stock | $0.00 | $50.3M | $125.4M | $4.5M | $61.6M | $76.0M | $1.5M | $82.8M | $0.00 | -$143.0K | $10.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$141.0K | $0.00 | -$22.0K | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$36.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $573.0K | $1.5M | $3.6M | $6.7M | $18.1M | $8.1M | $4.3M | $3.3M | $3.3M | $2.3M | $1.5M | |
| Net Change in Cash | -$39.8M | $6.2M | $39.3M | -$18.7M | $13.8M | -$15.6M | -$11.9M | -$301.0K | -$10.7M | $4.1M | $878.0K |
Dilution Tracker
Shares outstanding grew 2274.7% over 5 years — significant dilution
Shares Outstanding
9M
5-Year Share Growth
+2274.7%
Stock Issuance (TTM)
$10.0K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.06 | 0.06 | 0.21 | 0.85 | 0.86 | 0.86 | |
| Change vs Prior % | — | 0.0% | -5.7% | 56.6% | 282.1% | 58.7% | 11.4% | 222.4% | 314.6% | 0.4% | 0.3% | |
| Stock Issuance | $0.00 | $50.3M | $125.4M | $4.5M | $61.6M | $76.0M | $1.5M | $82.8M | $0.00 | -$143.0K | $10.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$141.0K | $0.00 | -$22.0K | |
| Stock Based Comp. | $573.0K | $1.5M | $3.6M | $6.7M | $18.1M | $8.1M | $4.3M | $3.3M | $3.3M | $2.3M | $1.5M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 100.0% | 21.0% | 93.4% | 100.0% | 100.0% | 100.0% | 100.0% | 96.0% | 97.5% | |
| Operating Margin % | -2126.4% | -645.9% | -512.5% | -17210.4% | 1203.0% | -4179.5% | -7189.7% | -6900.5% | -8710.0% | -5219.1% | -4134.6% | |
| Net Margin % | -2087.2% | -634.6% | -483.5% | -15906.1% | -1217.4% | -7876.4% | -4865.8% | -6710.4% | -7950.9% | -4646.1% | -3881.5% | |
| EBITDA Margin % | -2125.8% | -645.9% | -512.5% | -21237.7% | -1196.1% | -4086.0% | -7098.5% | -6573.6% | -7943.9% | -4685.8% | -3909.3% | |
| FCF Margin % | -344.5% | -617.1% | -496.9% | -14698.0% | -653.5% | -6054.5% | -6121.6% | -5976.7% | -6804.2% | -5811.2% | -3513.1% | |
| ROE % | 47.8% | 51.0% | -39.5% | -102.9% | -681.6% | -150.8% | -74.4% | -32.1% | -76.5% | -95.4% | -70.2% | |
| ROA % | -33.5% | -43.5% | -36.8% | -89.0% | -272.6% | -109.4% | -56.9% | -29.1% | -59.5% | -87.8% | -79.3% | |
| ROIC % | -37.6% | -50.1% | -41.8% | -105.3% | 346.9% | -79.4% | -109.2% | -32.4% | -83.6% | -107.1% | -90.3% | |
| R&D / Revenue % | 1669.9% | 633.1% | 498.0% | 12135.7% | 207.4% | 2099.1% | 3854.3% | 3846.0% | 6176.8% | 3374.9% | 2041.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 579.8% | 132.2% | -95.8% | 4638.8% | -95.6% | -48.8% | -11.1% | 18.2% | 13.8% | |
| Gross Profit | 0.0% | 579.8% | 132.2% | -99.1% | 20976.3% | -95.3% | -48.8% | -11.1% | 18.2% | 9.2% | |
| Operating Income | -211.0% | -106.5% | -84.3% | -39.8% | 431.2% | -115.4% | 11.9% | 14.7% | -49.1% | 31.8% | |
| Net Income | -205.3% | -106.7% | -76.9% | -37.0% | -262.7% | 71.3% | 68.3% | -22.6% | -40.0% | 33.5% | |
| EPS (Diluted) | -184.7% | -106.7% | -87.6% | -18.1% | 29.7% | 81.9% | 55.8% | 75.6% | 66.2% | 33.8% | |
| Operating Cash Flow | 45.2% | -1133.0% | -86.7% | -23.5% | -110.6% | 58.9% | 48.2% | 13.2% | -34.1% | 2.5% | |
| Free Cash Flow | 44.5% | -1117.7% | -87.0% | -23.1% | -110.7% | 58.9% | 48.2% | 13.2% | -34.5% | 2.8% | |
| R&D Expense | 285.3% | 157.7% | 82.7% | 1.5% | -19.0% | -55.1% | -5.9% | -11.3% | 89.8% | -37.8% | |
| SG&A Expense | 122.3% | 37.8% | 135.8% | 84.5% | 298.3% | -77.3% | -19.3% | -18.4% | -1.4% | -16.0% | |
| Total Assets | -4.2% | 59.0% | 109.3% | -43.4% | 18.4% | -28.5% | -39.2% | 139.7% | -31.5% | -54.9% | |
| Book Value / Share | -72.1% | -93.7% | 342.4% | -66.5% | -85.7% | -18.3% | -42.4% | -11.8% | -85.8% | -46.9% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 4869.1% | -99.0% | -100.0% | 0.0% | -53.7% | -100.0% | |
| Diluted Shares | 7.2% | 0.0% | -5.7% | 56.6% | 282.1% | 58.7% | 11.4% | 222.4% | 314.6% | 0.4% |
Valuation
P/E (TTM)At Loss
P/S301.14
10Y Low / Med / High8.39 / 56.45 / 978.66
P/B0.61
10Y Low / Med / High0.27 / 1.08 / 5.46
EV/EBITDAAt Loss
EV/Revenue253.57
10Y Low / Med / High1.38 / 141.73 / 972.69
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$23.72
Tangible Book / Share
$25.71
Net Current Assets / Share
$2.36
Graham Net-Net
$24.92
Cash / Share
$26.72
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -46.89 | -22.69 | -1.74 | -1.65 | -0.80 | -0.72 | -0.24 | -0.84 | -3.58 | -0.94 | -0.67 | |
| P/S Ratio | 978.66 | 143.96 | 8.39 | 355.46 | 9.76 | 56.38 | 18.03 | 56.45 | 284.78 | 43.53 | 301.14 | |
| P/B Ratio | -22.40 | -11.57 | 0.68 | 2.30 | 5.46 | 1.08 | 0.28 | 0.27 | 2.74 | 0.89 | 0.61 | |
| EV/EBITDA | -45.76 | -21.94 | -0.73 | -1.35 | -0.73 | -0.28 | 0.66 | 0.23 | -3.09 | -0.03 | -6.49 | |
| EV/Revenue | 972.69 | 141.73 | 3.74 | 287.57 | 8.67 | 11.37 | -46.76 | -15.26 | 245.20 | 1.38 | 253.57 |
Analyst Estimates & Quality
Altman Z-Score
9.65
Safe
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $530.2K | $493.1K | $458.7K |
| Net Income | -$76.1M | -$85.7M | -$81.3M |
| EPS | $-89.00 | $-100.25 | $-95.00 |
| # Analysts (EPS) | 1 | 1 | 1 |
Dividends
Dividend/Share (TTM)
$20.10
Dividend Yield
128.85%
Frequency
Irregular
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Jul 24, 2026 | $0.40 | Irregular |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|
| License | $10.0M | — | — | — | — |
| Product and Service, Other | — | — | — | — | — |
| Product | $10.2M | $13.8M | — | — | — |
| Royalty | $791.0K | $931.0K | $477.0K | — | — |
| Reportable Segment | — | — | — | $501.0K | $570.0K |